From: Okuzumi-Tatsuya(奥住 竜哉)
To: idangelo@amgen.com
Subject: [PepTalk] Amgen - Ajinomoto - Site-specific conjugation for ADC - Thank you
Date: Saturday, February 9, 2019 4:16:51 AM
Attachments: 2019-01-16 PepTalk 2019 AJINOMOTO Lunchon Presentation.pdf
image001.png
image003.png

Dear Igor D'Angelo,

It was great meeting you in PepTalk. Thank you very much for your interest in our ADC conjugation technology AJICAP™.
It would be great if you circulate the information to whom may have an interest on conjugation technology in your company.

Advantage of AJICAPtm is as follows:

1. Straightforward CMC
   - Direct modification of intact antibody
   - No genetic modification required
2. Enhancement of Therapeutic Window compared to stochastic ADCs
   - Site specific, controlled DAR 2
3. Wide drug-linker compatibility: reactive group compatibility includes thiol, alkyne, azide, etc
4. High yields, short conjugation reaction times, ease to manufacture

We have already developed 2nd generation AJICAP™ which has:

- More streamlined reaction sequence
- No red/ox reaction
- Less aggregation - below 1%.

We could introduce the detail of AJICAP™ via TC or email upon your request. Please feel free to ask questions if something is unclear. We are happy to answer.

Best regards,

TATSUYA OKUZUMI, Ph.D.
Associate General Manager - R&D planning Dept.
P: +81.70.4360.7840 | 1-15-1, Kyobashi, Chuo-ku, Tokyo 104-8315, JAPAN
AJINOMOTO CO., INC. | www.ajinomoto.com

Exhibit 1017
AJINOMOTO CO., INC.
IPR2025-00283